Study: NCT00364273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK159802
Description: GSK159802 will be available with dosing strengths of 75 microgram per blister and 300 microgram per blister administered using DISKUS inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK159802
Description: GSK159802 will be available with dosing strengths of 75 microgram per blister and 300 microgram per blister administered using DISKUS inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK159802
Description: GSK159802 will be available with dosing strengths of 75 microgram per blister and 300 microgram per blister administered using DISKUS inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK159802
Description: GSK159802 will be available with dosing strengths of 75 microgram per blister and 300 microgram per blister administered using DISKUS inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK159802
Description: GSK159802 will be available with dosing strengths of 75 microgram per blister and 300 microgram per blister administered using DISKUS inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK159802
Description: GSK159802 will be available with dosing strengths of 75 microgram per blister and 300 microgram per blister administered using DISKUS inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK159802
Description: GSK159802 will be available with dosing strengths of 75 microgram per blister and 300 microgram per blister administered using DISKUS inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK159802
Description: GSK159802 will be available with dosing strengths of 75 microgram per blister and 300 microgram per blister administered using DISKUS inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK159802
Description: GSK159802 will be available with dosing strengths of 75 microgram per blister and 300 microgram per blister administered using DISKUS inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK159802
Description: GSK159802 will be available with dosing strengths of 75 microgram per blister and 300 microgram per blister administered using DISKUS inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK159802
Description: GSK159802 will be available with dosing strengths of 75 microgram per blister and 300 microgram per blister administered using DISKUS inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK159802
Description: GSK159802 will be available with dosing strengths of 75 microgram per blister and 300 microgram per blister administered using DISKUS inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK159802
Description: GSK159802 will be available with dosing strengths of 75 microgram per blister and 300 microgram per blister administered using DISKUS inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK159802
Description: GSK159802 will be available with dosing strengths of 75 microgram per blister and 300 microgram per blister administered using DISKUS inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive placebo administered using DISKUS inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive placebo administered using DISKUS inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive placebo administered using DISKUS inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive placebo administered using DISKUS inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive placebo administered using DISKUS inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive placebo administered using DISKUS inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive placebo administered using DISKUS inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive placebo administered using DISKUS inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive placebo administered using DISKUS inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive placebo administered using DISKUS inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive placebo administered using DISKUS inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive placebo administered using DISKUS inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive placebo administered using DISKUS inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive placebo administered using DISKUS inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Description: Salmeterol will be available with dosing strength of 50 micrograms per blister administered using DISKUS inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Description: Salmeterol will be available with dosing strength of 50 micrograms per blister administered using DISKUS inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Description: Salmeterol will be available with dosing strength of 50 micrograms per blister administered using DISKUS inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Description: Salmeterol will be available with dosing strength of 50 micrograms per blister administered using DISKUS inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Description: Salmeterol will be available with dosing strength of 50 micrograms per blister administered using DISKUS inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Description: Salmeterol will be available with dosing strength of 50 micrograms per blister administered using DISKUS inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Description: Salmeterol will be available with dosing strength of 50 micrograms per blister administered using DISKUS inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Description: Salmeterol will be available with dosing strength of 50 micrograms per blister administered using DISKUS inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Description: Salmeterol will be available with dosing strength of 50 micrograms per blister administered using DISKUS inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Description: Salmeterol will be available with dosing strength of 50 micrograms per blister administered using DISKUS inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Description: Salmeterol will be available with dosing strength of 50 micrograms per blister administered using DISKUS inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Description: Salmeterol will be available with dosing strength of 50 micrograms per blister administered using DISKUS inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Description: Salmeterol will be available with dosing strength of 50 micrograms per blister administered using DISKUS inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Description: Salmeterol will be available with dosing strength of 50 micrograms per blister administered using DISKUS inhaler.